Spectrum (SPPI) Beats on Revenue, Misses on EPS

Spectrum Pharmaceuticals, Inc. (SPPI) gained $0.29 to $6.55 in pre-market session Friday after it reported fiscal-fourth quarter earnings. The biotech firm handed in non-GAAP earnings of $0.09 per share on revenue of $51.9 million, vs. Wall Street estimates of $0.12 per share on revenue of $48.73 million. For the twelve-month period ended December 31, 2014, […] View the full post at: Spectrum (SPPI) Beats on Revenue, Misses on EPS Related posts: Rethinking California’s Revenue Structure JPMorgan Posts Better-than-Expected Results Fidelity Discloses 14.97% stake in Ariad